Common use of TABLE OF DEFINED TERMS Clause in Contracts

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(b) Acquired Company Introduction Acquired Company IP 2.11(a) Acquired Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(i) Affiliate 2.1(b) Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(a) Bankruptcy and Equity Exception 2.3 Business Day 1.3(a)(ii) Business Material Adverse Effect 2.1(b) Business Introduction Buyer Preliminary Statement Buyer Material Adverse Effect 3.3(b) Cap 4.5(a)(i) Claim Notice 4.3(b) Claimed Amount 4.3(b) Closing 1.2(a) Closing Cash 1.3(a)(iii) Closing Date 1.2(a) Closing Indebtedness 1.3(a)(iv) Code 2.8(d) Commissions Receivable Adjustment 1.3(a)(v) Commissions Receivable Factor 1.3(a)(vi) Competitive Business 6.2 Covered Individual 6.2 COVID-19 2.1(b) COVID-19 Measures 2.1(b) COVID-19 Responses 2.1(b) Damages 4.1; 4.3(a) Deductible 4.5(a)(ii) Designated Contracts 2.12(b) Designated Intellectual Property 2.11(a) Disclosing Party 6.1(e) Disclosure Schedule Article II Dispute Notice 1.3(d) Employee Benefit Plan 2.15(a) Environmental Laws 2.21(a) Equity Interests Introduction ERISA 2.15(a) Defined Term Section ERISA Affiliate 2.15(a) Estimated Closing Statement 1.3(b) Estimated Purchase Price 1.3(b) Excluded Liabilities 4.1 Final Closing Statement 1.3(c) Final Purchase Price 1.3(c)

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(bAcceptable Confidentiality Agreement 6.8(b) Acquired Company Introduction Acquired Company IP 2.11(aAcceptance Time 1.3(a) Acquired Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(iAction 6.9(b) Affiliate 2.1(b) Transaction 3.22 Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(aPreamble Appraisal Shares 2.6 Alternative Acquisition Agreement 6.8(a) Bankruptcy and Equity Exception 2.3 Business Day 1.3(a)(ii3.3(a) Business Material Adverse Effect 2.1(bBoard Appointment Date 1.3(a) Business Introduction Buyer Preliminary Statement Buyer Material Adverse Effect 3.3(bBoard Recommendation 3.3(d) Cap 4.5(a)(iBook-Entry Shares 2.7(b) Claim Notice 4.3(bCertificate 2.7(b) Claimed Amount 4.3(bCertificate of Merger 2.2(b) Closing 1.2(a) Closing Cash 1.3(a)(iii2.2(a) Closing Date 1.2(a2.2(a) Closing Indebtedness 1.3(a)(ivCOBRA 3.10(g) Code 2.8(dCompany Preamble Company Adverse Recommendation Change 6.8(c) Commissions Receivable Adjustment 1.3(a)(vCompany Board 1.2(c) Commissions Receivable Factor 1.3(a)(viCompany Charter Documents 3.1(b) Competitive Business 6.2 Covered Individual 6.2 COVID-19 2.1(bCompany Disclosure Documents 3.8(a) COVID-19 Measures 2.1(bCompany Disclosure Letter 3 Company Employee 6.2(a) COVID-19 Responses 2.1(bCompany Equity Award 3.2(b) Damages 4.1; 4.3(aCompany Financial Advisor 3.16 Company Financial Statements 3.5(b) Deductible 4.5(a)(iiCompany Material Contract 3.18(a) Designated Contracts 2.12(bCompany Preferred Stock 3.2(a) Designated Company Registered Intellectual Property 2.11(a3.15(b) Disclosing Party 6.1(eCompany SEC Reports 3.5(a) Disclosure Schedule Article II Dispute Notice 1.3(dCompany Securities 3.2(d) Company Stockholders Meeting 6.1(b) Company Voting Proposal 6.1(b) Compensation Committee 3.2(f) Confidentiality Agreement 6.7(b) Constituent Corporations 2.1 Continuing Directors 1.3(a) D&O Insurance 6.9(c) DGCL Recitals DOJ 6.3(a) DOL 3.10(b) Drug Regulatory Laws 3.14(c) Effective Time 2.2(b) Employee Benefit Plan 2.15(a3.10(a) Environmental Laws 2.21(a) Equity Interests Introduction ERISA 2.15(a) Defined Term Section Environmental Costs 3.13(a)(1) ERISA Affiliate 2.15(a3.10(e) Estimated Closing Exchange Agent 2.7(a) Exchange Fund 2.7(a) Expiration Date 1.1(b) FCPA 3.5(g) FDCA 3.14(c) Federal False Claims Act 3.14(h) Federal Fraud Statutes 3.14(h) FTC 6.3(a) GAAP 3.5(b) Governmental Authority 3.3(c) Health Regulatory Laws 3.14(h) HIPAA 3.14(h) HSR Act 3.3(c) Indemnified Party 6.9(a) INDs 3.14(d) Information Statement 1.3(b3.3(c) Estimated Purchase Price 1.3(bIntellectual Property 3.15(a) Excluded Liabilities 4.1 Final Closing Statement 1.3(cJudgment 3.3(b) Final Purchase Price 1.3(cLaw 3.3(b) Leased Real Property 3.19(a) Leases 3.19(a) Maximum Amount 6.9(c) Merger Recitals Merger Consideration 2.5(a) Merger Sub Preamble Minimum Tender Condition Annex A NDA 3.14(c) NOL Carryforwards 3.12(l) Notice of Superior Proposal 6.8(d)

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(bAcceptance Time 1.3(a) Acquired Accredited Investor 2.7(d) Acquisition Agreement 7.1(b) Acquisition Proposal 7.1 Adverse Recommendation Notice 7.1(b) Affiliate 4.2(e) Agreement Introduction Approved Company Compensation Arrangement 4.23 Certificate of Merger 2.3 Certificate 3.1(a) CLIA 4.15(o) Closing 2.2 Closing Date 2.2 Code 1.1(e) Company Introduction Acquired Company IP 2.11(aAdverse Recommendation Change 9.1(c) Acquired Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(i) Affiliate 2.1(b) Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(a4.5(b) Bankruptcy and Equity Exception 2.3 Business Day 1.3(a)(iiCompany Board 1.2(b) Business Company Capital Stock 3.2(c) Company Common Stock Introduction Company Compensation Arrangement 4.23 Company Disclosure Schedule Article IV Company Employees 7.8(a) Company Employee Plans 4.14(a) Company Intellectual Property 4.10(b) Company Leases 4.9(b) Company Material Adverse Effect 2.1(b4.1 Company Material Contracts 4.11(a) Business Introduction Buyer Preliminary Statement Buyer Material Adverse Effect 3.3(bCompany Permits 4.16 Company Preferred Stock 4.2(a) Cap 4.5(a)(iCompany SEC Documents 4.5(a) Claim Notice 4.3(bCompany Stockholder Approval 4.4(a) Claimed Amount 4.3(bCompany Stockholders Meeting 7.4(a) Closing 1.2(aCompany Stock Options 4.2(c) Closing Cash 1.3(a)(iiiCompany Stock Plans 4.2(c) Closing Date 1.2(aCompany Voting Proposal 4.4(a) Closing Indebtedness 1.3(a)(ivCompany Warrants 4.2(d) Code 2.8(d) Commissions Receivable Adjustment 1.3(a)(v) Commissions Receivable Factor 1.3(a)(vi) Competitive Business Compensation Committee 4.23 Confidentiality Agreement 6.2 Covered Individual 6.2 COVID-19 2.1(b) COVID-19 Measures 2.1(b) COVID-19 Responses 2.1(b) Damages 4.1; 4.3(a) Deductible 4.5(a)(iiContamination 4.12(c) Designated Contracts 2.12(bSEC Documents Article IV DGCL Introduction Dissenting Shares 3.1(b) Designated Intellectual Property 2.11(a) Disclosing Party 6.1(e) Disclosure Schedule Article II Dispute Notice 1.3(d) Effective Time 2.3 Employee Benefit Plan 2.15(a4.14(a) Environmental Laws 2.21(aLaw 4.13(b) Equity Interests Introduction ERISA 2.15(a4.14(a) Defined Term Section ERISA Affiliate 2.15(a4.14(a) Estimated Closing Statement 1.3(b) Estimated Purchase Price 1.3(b) Excluded Liabilities 4.1 Final Closing Statement 1.3(c) Final Purchase Price 1.3(c)Exchange Act 1.1 ESPP 7.9

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(bDEFINED TERM SECTION PAGE 2006 Dividend 6.15(b)(vii) Acquired 44 Adverse Recommendation Notice 5.02(d) 37 Affiliate 9.03(a) 52 Agreement Preamble 1 Carryover PTO 6.08(b) 41 Certificate 2.01(c)(v) 3 Certificate of Merger 1.03 2 Closing 1.02 2 Closing Date 1.02 2 Closing Merger Consideration 2.01(c) 3 Closing Merger Consideration Per Share 2.01(c)(ii) 3 COBRA 3.12(h) 19 Code 2.04 6 Company Introduction Acquired Adverse Recommendation Change 5.02(d) 36 Company IP 2.11(aBy-laws 3.01 7 Company Certificate 3.01 7 Company Closing Cash 6.14 43 Company Common Stock 2.01 2 Company Disclosure Letter Article III 7 Company Intellectual Property 3.14(a)(iv) Acquired 22 Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(i) Affiliate 2.1(b) Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(a) Bankruptcy and Equity Exception 2.3 Business Day 1.3(a)(ii) Business Material Adverse Effect 2.1(b3.04(c) Business Introduction Buyer Preliminary Statement Buyer 11 Company Plans 3.12(a) 18 Company Preamble 1 Company Preferred Stock 3.03(a) 8 Company SEC Documents 3.06(a) 12 Company Stock Option 2.03(a) 6 Company Stock Plans 3.03(a) 8 Company Stockholder Approval 3.04(a) 10 Company Stockholders Meeting 6.01(b) 38 Company Superior Proposal 5.02(c) 36 Company Takeover Proposal 5.02(b) 35 Company’s Transaction Expenses 6.15(b)(ii) 43 Confidentiality Agreement 6.02(a) 38 Contract 3.04(b) 10 Copyrights 3.14(a)(i)(C) 22 DGCL 1.01 1 Dissenting Shares 2.02(h) 5 Effective Time 1.03 2 Eligible Employees 6.08(b) 41 Employees 3.12(a) 18 ENS Purchase Agreement 6.12 42 Environmental Laws 3.16(b) 26 Environmental Liabilities 3.16(c) 26 ERISA 3.12(a) 17 Estimated Balance Sheet 6.14 43 Exchange Agent 2.02(a) 3 Exchange Fund 2.02(a) 4 Filed Company SEC Documents 3.08 13 Fully-Diluted Common Stock Number 2.01(c)(i) 3 GAAP 3.06(b) 12 Governmental Authority 3.05 11 Hazardous Material 3.16(d) 26 Indemnified Parties 6.04(a) 40 Information Supplies 3.07 12 Insider Settlement 6.17 44 Intellectual Property 3.14(a)(i) 22 IP Licenses 3.14(a)(ii) 22 IRS 3.13(c) 20 Knowledge 9.03(b) 53 Laws 3.11(a) 15 Leases 3.15(a) 25 Liens 3.02 7 Management Bonuses 6.15(b)(iii) 43 Merger Preamble 1 Merger Sub Preamble 1 Mogul Sub 3.03(c) 8 Mogul Sub Capital Stock 3.03(c) 8 Mogul Sub Common Stock 3.03(c) 8 Mogul Sub Preferred Stock 3.03(c) 8 Mogul Sub Stock Options 3.03(c) 9 Mogul Sub Stock Plans 3.03(c) 9 Necessary Consents 3.05 11 NY Office Wind-Down Costs 6.15(b)(v) 44 Parent Disclosure Letter Article IV 28 Parent Material Adverse Effect 3.3(b4.02(c) Cap 4.5(a)(i29 Parent Preamble 1 Patents 3.14(a)(i)(B) Claim Notice 4.3(b22 Permits 3.11(a) Claimed Amount 4.3(b16 Permitted Liens 9.03(d) Closing 1.2(a53 person 9.03(c) Closing 53 poison pill 5.01(a)(iii) 31 Proprietary Software 3.14(j) 24 Real Property 3.15(a) 25 Release 3.16(e) 27 Representatives 5.02(a) 35 Requisite Regulatory Approvals 7.01(b) 45 Restraints 7.01(c) 45 Rights Agreement 3.22 28 Xxxxxxxx-Xxxxx 3.11(e) 16 Securities Act 3.03(e) 9 Severance Costs 6.15(b)(iv) 44 Software 3.14(a)(iii) 22 Statement of Estimated Company Cash 1.3(a)(iii6.14 43 Subsidiary 9.03(e) Closing 53 Surviving Corporation 1.01 1 Target Company Cash 6.15 43 tax returns 3.13(l) 21 taxes 3.13(l) 21 Termination Date 1.2(a8.01(b)(i) Closing Indebtedness 1.3(a)(iv48 Termination Fee 8.02(a)(iv) Code 2.8(d50 Trade Secrets 3.14(a)(i)(D) Commissions Receivable Adjustment 1.3(a)(v22 Trademarks 3.14(a)(i)(A) Commissions Receivable Factor 1.3(a)(vi22 Voting Agreement Preamble 1 Wind-Down Costs 6.15(b)(vi) Competitive Business 6.2 Covered Individual 6.2 COVID-19 2.1(b) COVID-19 Measures 2.1(b) COVID-19 Responses 2.1(b) Damages 4.1; 4.3(a) Deductible 4.5(a)(ii) Designated Contracts 2.12(b) Designated Intellectual Property 2.11(a) Disclosing Party 6.1(e) Disclosure Schedule Article II Dispute Notice 1.3(d) Employee Benefit Plan 2.15(a) Environmental Laws 2.21(a) Equity Interests Introduction ERISA 2.15(a) Defined Term Section ERISA Affiliate 2.15(a) Estimated Closing Statement 1.3(b) Estimated Purchase Price 1.3(b) Excluded Liabilities 4.1 Final Closing Statement 1.3(c) Final Purchase Price 1.3(c44 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of May 25, 2006, is by and among Ingenix, Inc., a Delaware corporation (“Parent ”), Mogul Acquisition Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”), and NWH, Inc., a Delaware corporation (the “Company”).

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(bDEFINED TERM SECTION PAGE 2006 Dividend 6.15(b)(vii) Acquired 44 Adverse Recommendation Notice 5.02(d) 37 Affiliate 9.03(a) 52 Agreement Preamble 1 Carryover PTO 6.08(b) 41 Certificate 2.01(c)(v) 3 Certificate of Merger 1.03 2 Closing 1.02 2 Closing Date 1.02 2 Closing Merger Consideration 2.01(c) 3 Closing Merger Consideration Per Share 2.01(c)(ii) 3 COBRA 3.12(h) 19 Code 2.04 6 Company Introduction Acquired Adverse Recommendation Change 5.02(d) 36 Company IP 2.11(aBy-laws 3.01 7 Company Certificate 3.01 7 Company Closing Cash 6.14 43 Company Common Stock 2.01 2 Company Disclosure Letter Article III 7 Company Intellectual Property 3.14(a)(iv) Acquired 22 Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(i) Affiliate 2.1(b) Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(a) Bankruptcy and Equity Exception 2.3 Business Day 1.3(a)(ii) Business Material Adverse Effect 2.1(b3.04(c) Business Introduction Buyer Preliminary Statement Buyer 11 Company Plans 3.12(a) 18 Company Preamble 1 Company Preferred Stock 3.03(a) 8 Company SEC Documents 3.06(a) 12 Company Stock Option 2.03(a) 6 Company Stock Plans 3.03(a) 8 Company Stockholder Approval 3.04(a) 10 Company Stockholders Meeting 6.01(b) 38 Company Superior Proposal 5.02(c) 36 Company Takeover Proposal 5.02(b) 35 Company’s Transaction Expenses 6.15(b)(ii) 43 Confidentiality Agreement 6.02(a) 38 Contract 3.04(b) 10 Copyrights 3.14(a)(i)(C) 22 DGCL 1.01 1 Dissenting Shares 2.02(h) 5 Effective Time 1.03 2 Eligible Employees 6.08(b) 41 Employees 3.12(a) 18 ENS Purchase Agreement 6.12 42 Environmental Laws 3.16(b) 26 Environmental Liabilities 3.16(c) 26 ERISA 3.12(a) 17 Estimated Balance Sheet 6.14 43 Exchange Agent 2.02(a) 3 Exchange Fund 2.02(a) 4 Filed Company SEC Documents 3.08 13 Fully-Diluted Common Stock Number 2.01(c)(i) 3 GAAP 3.06(b) 12 Governmental Authority 3.05 11 Hazardous Material 3.16(d) 26 Indemnified Parties 6.04(a) 40 Information Supplies 3.07 12 Insider Settlement 6.17 44 Intellectual Property 3.14(a)(i) 22 IP Licenses 3.14(a)(ii) 22 IRS 3.13(c) 20 Knowledge 9.03(b) 53 Laws 3.11(a) 15 Leases 3.15(a) 25 Liens 3.02 7 Management Bonuses 6.15(b)(iii) 43 Merger Preamble 1 Merger Sub Preamble 1 Mogul Sub 3.03(c) 8 Mogul Sub Capital Stock 3.03(c) 8 Mogul Sub Common Stock 3.03(c) 8 Mogul Sub Preferred Stock 3.03(c) 8 Mogul Sub Stock Options 3.03(c) 9 Mogul Sub Stock Plans 3.03(c) 9 Necessary Consents 3.05 11 NY Office Wind-Down Costs 6.15(b)(v) 44 Parent Disclosure Letter Article IV 28 Parent Material Adverse Effect 3.3(b4.02(c) Cap 4.5(a)(i29 Parent Preamble 1 Patents 3.14(a)(i)(B) Claim Notice 4.3(b22 Permits 3.11(a) Claimed Amount 4.3(b16 Permitted Liens 9.03(d) Closing 1.2(a53 person 9.03(c) Closing 53 poison pill 5.01(a)(iii) 31 Proprietary Software 3.14(j) 24 Real Property 3.15(a) 25 Release 3.16(e) 27 Representatives 5.02(a) 35 Requisite Regulatory Approvals 7.01(b) 45 Restraints 7.01(c) 45 Rights Agreement 3.22 28 Xxxxxxxx-Xxxxx 3.11(e) 16 Securities Act 3.03(e) 9 Severance Costs 6.15(b)(iv) 44 Software 3.14(a)(iii) 22 Statement of Estimated Company Cash 1.3(a)(iii6.14 43 Subsidiary 9.03(e) Closing 53 Surviving Corporation 1.01 1 Target Company Cash 6.15 43 tax returns 3.13(l) 21 taxes 3.13(l) 21 Termination Date 1.2(a8.01(b)(i) Closing Indebtedness 1.3(a)(iv48 Termination Fee 8.02(a)(iv) Code 2.8(d50 Trade Secrets 3.14(a)(i)(D) Commissions Receivable Adjustment 1.3(a)(v22 Trademarks 3.14(a)(i)(A) Commissions Receivable Factor 1.3(a)(vi22 Voting Agreement Preamble 1 Wind-Down Costs 6.15(b)(vi) Competitive Business 6.2 Covered Individual 6.2 COVID-19 2.1(b) COVID-19 Measures 2.1(b) COVID-19 Responses 2.1(b) Damages 4.1; 4.3(a) Deductible 4.5(a)(ii) Designated Contracts 2.12(b) Designated Intellectual Property 2.11(a) Disclosing Party 6.1(e) Disclosure Schedule Article II Dispute Notice 1.3(d) Employee Benefit Plan 2.15(a) Environmental Laws 2.21(a) Equity Interests Introduction ERISA 2.15(a) Defined Term Section ERISA Affiliate 2.15(a) Estimated Closing Statement 1.3(b) Estimated Purchase Price 1.3(b) Excluded Liabilities 4.1 Final Closing Statement 1.3(c) Final Purchase Price 1.3(c44 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of May 25, 2006, is by and among Ingenix, Inc., a Delaware corporation (“Parent”), Mogul Acquisition Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”), and NWH, Inc., a Delaware corporation (the “Company”).

TABLE OF DEFINED TERMS. Defined Term Section Accounting Principles 1.3(bAcquisition Transactions 5.8(a) Acquired Company Introduction Acquired Company IP 2.11(a) Acquired Company Released Persons 6.8 Adjusted Purchase Price 1.3(j) Adjustment Threshold 1.3(i) Affiliate 2.1(b) Advisory Board 6.5 Agreement Preliminary Statement Assumed Liabilities 4.2 Balance Sheet 2.6(a) Bankruptcy and Equity Exception 2.3 Recitals BHC Act Recitals Business Day 1.3(a)(ii10.12 Closing 1.2 Closing Date 1.2 Code 3.17(a)(1) Business Community Trust Bank Recitals Confidentiality Agreement 10.9 Continuing Employee 6.2(a) Core Deposits 7.1(h) CTBI Preamble Department 3.17(a)(1) Disclosure Schedule 5.8(a) Dissenting Shares 2.4 Effective Time 1.3 Environmental Laws 3.14(a) ERISA 3.17(a) FDIC 3 Exchange Agent 2.2 GAAP 3 Governmental Authority 5.15 Hazardous Substance 3.14(a) Indemnified Parties 5.17(b) Knowledge 3 LaFollette Bank Preamble LaFollette Corporation Preamble LaFollette Corporation Common Stock 1.4 LaFollette Corporation Financial Statements 3.9(a) LaFollette Corporation Insiders 3.26 LaFollette Corporation Plans 3.17(a) LaFollette Regulatory Filings 3.8 Material Adverse Effect 2.1(b3 Non-Compete Agreements 5.20 Offer Notification 5.8(b) Business Introduction Buyer Preliminary Statement Buyer Material Adverse Effect 3.3(bOREO 3.11(a)(1) Cap 4.5(a)(i) Claim Notice 4.3(b) Claimed Amount 4.3(b) Closing 1.2(a) Closing Cash 1.3(a)(iii) Closing Date 1.2(a) Closing Indebtedness 1.3(a)(iv) Code 2.8(d) Commissions Receivable Adjustment 1.3(a)(v) Commissions Receivable Factor 1.3(a)(vi) Competitive Business 6.2 Covered Individual 6.2 COVID-19 2.1(b) COVID-19 Measures 2.1(b) COVID-19 Responses 2.1(b) Damages 4.1; 4.3(a) Deductible 4.5(a)(ii) Designated Contracts 2.12(b) Designated Intellectual Property 2.11(a) Disclosing Parties Preamble Party 6.1(e) Disclosure Schedule Article II Dispute Notice 1.3(d) Employee Benefit Plan 2.15(a) Environmental Laws 2.21(a) Equity Interests Introduction ERISA 2.15(a) Defined Term Section ERISA Affiliate 2.15(a) Estimated Closing Statement 1.3(b) Estimated Preamble Purchase Price 1.3(b2.1(a) Excluded Liabilities 4.1 Final Closing Statement 1.3(cSEC 3.26 Share Exchange 1.1 Service 3.17(a)(2) Final Purchase Price 1.3(cSubsequent LaFollette Corporation Financial Statements 5.13 TBCA 2.4 Termination Fee 8.3(a) VEBA 3.17(g)